UNSPSC 51271803: Propanidid

This classification denotes an anesthetic agent with the molecular formula C18H27NO5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AO82L471NS, chemically known as benzeneacetic acid, 4-(2-(diethylamino)-2-oxoethoxy)-3-methoxy-, propyl ester but generally known as propanidid, which bears US NIH Compound Identifier 15004. European Medicines Agency schedules Propanidid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10096MIG. The term PROPANIDID is an International Non-Proprietary Name.

UNSPSC 51271803 Propanidid, a Commodity code, covers anesthetic pharmaceuticals supplied through state and local cooperative purchasing vehicles and direct agency procurement. State and local governments buy propanidid and related intravenous anesthetics primarily through multistate cooperative agreements, with purchasing concentrated among state health departments, hospital systems within state agencies, correctional facilities, and other clinical settings requiring anesthesia supply chains. The scope includes not only the active pharmaceutical ingredient but also finished dosage forms meeting FDA requirements, cGMP certification, and Drug Supply Chain Security Act compliance. Issuing bodies are predominantly state purchasing offices administering multistate cooperative agreements, though the code also covers direct RFQs and ITBs from individual state departments, county health authorities, and hospital networks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products, with propanidid and similar anesthetics eligible under the broader pharmaceutical scope. The MMCAP agreement serves Minnesota and Oregon participating entities and uses three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—to distribute awarded products. Vendors must maintain contractual relationships with at least two of the three wholesalers, certify cGMP and DSCSA compliance, carry commercial general liability coverage of $5 million per occurrence and professional liability of $2 million, and submit pricing in flat-price or net-price formats through the ePro procurement system by March 26, 2026. Evaluations emphasize price competitiveness (75 percent) alongside compliance, EDI capability, and administrative-fee agreement, with awarded contracts effective July 1, 2026 for an initial two-year term.